Status:
COMPLETED
A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine
Lead Sponsor:
Diamond Headache Clinic
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Migraine
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to test an experimental drug combination of two medications currently approved by the Food and Drug Administration (FDA) for migraine headache or other pain. These are cal...
Eligibility Criteria
Inclusion
- Subject is at least 18 years of age
- Subject has at least a 6 month history of migraine, with or without aura
- Subject can distinguish between migraine attacks and other types of headaches
- Subject of childbearing potential agrees to use adequate contraception
Exclusion
- Subject typically has fewer than 1 or greater than 6 migraine attacks per month
- Subject typically has greater than 10 headache days per month
- Subject has evidence of ischemic heart disease
- Subject has uncontrolled high blood pressure
- Subject has a history, within 1 year, or current evidence of drug or alcohol abuse
- \*This list is not all inclusive\*
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
End Date :
January 1 2007
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00300924
Start Date
March 1 2006
End Date
January 1 2007
Last Update
May 28 2008
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
SanFrancisco Headache Clinic
San Francisco, California, United States, 94109
2
Diamond Headache Clinic
Chicago, Illinois, United States, 60614
3
Westside Family Medical Center
Kalamazoo, Michigan, United States, 49009
4
Clinvest
Springfield, Missouri, United States